Our Take
Cost containment without outcome measurement is cost-shifting, not cost control, and it compounds the problem.
Why it matters
Health plans operate under margin pressure and face renewed scrutiny on care quality. Surgical cost management that ignores outcomes data leaves plans exposed to both financial leakage and regulatory risk.
Do this week
Benefits director: audit your surgical pre-authorization criteria against your own outcomes data before Q2 budget review so you can identify which denials actually improve margin versus which ones just defer cost.
The surgery avoidance trap
Health plans have invested heavily in surgical cost containment strategies, primarily through pre-authorization and referral management. The focus has been straightforward: reduce the number of surgeries approved, lower the per-case spend. But Healthcare Dive reports that many plans are stopping there, treating surgery avoidance as the end goal rather than the beginning of a cost discipline problem.
The gap is outcomes optimization. Plans that approve fewer surgeries without measuring whether those decisions improve or degrade patient outcomes are essentially gambling with claims data. A denied surgery that prevents harm saves money. A denied surgery that delays necessary intervention and leads to costlier downstream care or complications does not.
The distinction matters because it determines whether a cost reduction is real or borrowed from tomorrow's claims.
What gets measured gets managed
The arithmetic is simple but often invisible. A plan that blocks 10% of requested surgeries looks good on a cost report. But if those blocked cases include some percentage of medically necessary procedures, the plan has not reduced cost; it has redistributed it. Patients may end up in emergency departments, require longer hospital stays, or need more intensive post-operative care when eventual treatment finally occurs.
Plans that pair surgical utilization management with outcomes tracking can identify which authorization rules actually work and which ones are just friction. This is not speculation. It is operationalization of the oldest principle in managed care: you cannot optimize what you do not measure.
Regulatory and reputational risk adds weight. Health plans operate under increasing scrutiny on care quality scores and medical loss ratios. A plan that systematically reduces surgical approvals without demonstrating improved outcomes or quality metrics may face pushback from employers, regulators, or insurers themselves on whether the savings are defensible.
How to close the gap
The fix requires three parallel tracks. First, establish a baseline. Audit your current surgical pre-authorization denials and link them to subsequent claims and readmissions. Identify which denials correlate with better outcomes and which ones correlate with higher downstream costs. You may find that 30% of your denials are actually cost-positive and another 40% break even.
Second, rebuild your authorization rules around outcomes, not just volume. If your data shows that denying knee arthroscopy in patients over 65 actually increases total cost due to emergency interventions, change the rule. If pre-authorization for joint replacement in specific conditions improves outcomes and reduces 12-month spend, codify it.
Third, close the loop with your surgical networks and in-house clinical teams. Share the outcomes data with them. Plans that treat surgery avoidance as shared savings rather than plan-only wins tend to see less gaming and more genuine collaboration on which cases benefit from intervention.
The companies claiming to solve this problem are selling outcomes-tracking software and pre-authorization platforms, but the real work is internal: linking your authorization decisions to your claims data and making that linkage visible to the people making the decisions.